Weekly Roundup: August 3-7

August 7, 2020

ICYMI, this week we featured a new episode of The Cutaneous Connection, a hyperspectral technology company helping to investigate COVID-19-related skin findings, cannabinoid-containing products and their effects on prescription medications, plus more.

In case you missed it, this week we released a new episode of our podcast The Cutaneous Connection discussing probiotics as a possible treatment for psoriasis and other inflammatory skin diseases. We also featured articles on a hyperspectral technology company helping to investigate COVID-19-related skin findings, cannabinoid-containing products and their effects on prescription medications, the U.S. Food and Drug Administration (FDA) granting a Fast Track Designation to delgocitinib for chronic hand eczema, plus more.

The Mainstream Patient: August 3

This week’s edition of The Mainstream Patient features stories about sun spots, niacinamide, proper body hair removal, psoriasis-related mental health treatment, plus more.

Can value-based care save your practice?

Due to the financial fallout caused by COVID-19, many practices are struggling to keep their doors open. What options to physicians have? This expert says hope lies within value-based care.

App improves office efficiency and communication with patients

Demandforce introduces their mobile app, which is available free to all Demandforce users and is aimed at making practice operations and the lives of physicians easier through streamlined communication and office efficiency.

Expansion of telehealth benefits may become permanent

The Centers for Medicare & Medicaid Services (CMS) has proposed a permanent expansion of telehealth to ensure healthcare access in rural areas.

Silicone pads aim to reduce mouth lines

SilcSkin introduces their Multi-Area Pads to help treat fine lines and wrinkles in the mouth area.

EC approves secukinumab for pediatric psoriasis

The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients ages 6 to 17 years in the European Union.

ACP supports changes to Medicare fee schedule

The American College of Physicians (ACP) claims the changes to payments for offices visits will benefit physicians and practices.

Cannabinoid products may alter effects of prescription drugs

Researchers have identified and developed lists of medications that may not function properly due to concomitant cannabinoid use in an effort to help medical professionals prescribe drugs safely to their patients.

Study: Pay gap slightly narrowed for primary care, specialist under ACA

A recently published study finds from 2008 to 2017, primary care physicians received only a slightly greater rise in compensation than specialists under the 2010 Affordable Care Act.

FDA grants delgocitinib fast track designation for chronic hand eczema

The U.S. Food and Drug Administration (FDA) has granted JAK-inhibitor delgocitinib cream (LEO Pharma) Fast Track Designation for chronic hand eczema.

The Cutaneous Connection: Episode 4- Probiotics for Psoriasis?

This episode dives into emerging research regarding probiotics specifically tailored to treat psoriasis and possibly other inflammatory skin diseases.

HinaLea Imaging helps research COVID-19 skin manifestations

Hyperspectral imaging company HinaLea Imaging is using their technology to study the skin manifestations of patients who are critically ill with COVID-19 to help identify the prognostic value of these skin symptoms.

Herbal cream as effective as hydroquinone for melasma

Researchers examined a group of adult women diagnosed with melasma who applied a traditional medicinal product on one side of their face and 4% hydroquinone on the other side.

How will COVID-19 impact value-based models?

COVID-19 has left providers with fewer in-office visits, more telehealth appointments and, for many, reduced revenue.

FDA approves ustekinumab for pediatric psoriasis

The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.